



Tanvex BioPharma, Inc. held road show presentation

Taipei, Taiwan, January 17, 2018

Tanvex BioPharma, Inc. ("Tanvex", stock code 6541) held a road show presentation on January 17, 2018 hosted by Dr. Allen Chao.

According to Dr. Chao, CEO of Tanvex, the Company has completed phase III clinical trials on TX01, a proposed biosimilar to Neupogen®(filgrastim), and expect to file the BLA for TX01 in 2018 as planned. The Company remains on schedule for commercial manufacturing of TX01 in 2019 and has also solidified its sales and marketing team to prepare for launch in 2019.

In the past year, Tanvex has kept its promises to investors completing phase III clinical trials for TX01 and completing phase I clinical trials for TX16. In addition, Tanvex has initiated phase III clinical trials for TX05.

Tanvex's rapid and successful growth has garnered critical acclaim and attention in the industry. Tanvex also participated in JP Morgan's 36th Annual Healthcare Conference held from January 8, to January 11, 2018 in San Francisco. At the conference, Dr. Chao shared with participants the Company's latest developments, future projects and goals.